The European advisory group CHMP has adopted a positive opinion recommending approval of Merck’s (NYSE:MRK)
V920 Ebola Zaire vaccine, branded as ERVEBO, for active immunization of
people at least 18 years old to protect against Ebola Virus Disease
(EVD) caused by the Zaire Ebola virus.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3506814-european-advisory-group-backs-merck-ebola-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.